CA2678007A1 - Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations - Google Patents

Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations Download PDF

Info

Publication number
CA2678007A1
CA2678007A1 CA002678007A CA2678007A CA2678007A1 CA 2678007 A1 CA2678007 A1 CA 2678007A1 CA 002678007 A CA002678007 A CA 002678007A CA 2678007 A CA2678007 A CA 2678007A CA 2678007 A1 CA2678007 A1 CA 2678007A1
Authority
CA
Canada
Prior art keywords
pyrrolo
pyridine
group
pyrimidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002678007A
Other languages
English (en)
French (fr)
Inventor
Laurent Meijer
Benoit Joseph
Francois Liger
Bernard Marquet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie
Universite Claude Bernard Lyon 1
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2678007A1 publication Critical patent/CA2678007A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002678007A 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations Abandoned CA2678007A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0701138A FR2912744B1 (fr) 2007-02-16 2007-02-16 Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
FR0701138 2007-02-16
PCT/FR2008/000197 WO2008129152A1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2678007A1 true CA2678007A1 (fr) 2008-10-30

Family

ID=38515529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002678007A Abandoned CA2678007A1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations

Country Status (6)

Country Link
US (1) US20100184790A1 (OSRAM)
EP (1) EP2125803B1 (OSRAM)
JP (1) JP2010518153A (OSRAM)
CA (1) CA2678007A1 (OSRAM)
FR (1) FR2912744B1 (OSRAM)
WO (1) WO2008129152A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
EP2454257B1 (en) * 2009-07-15 2013-08-21 AbbVie Inc. Pyrrolopyridine inhibitors of kinases
CA2878054C (en) 2012-06-29 2018-09-11 Pfizer Inc. Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
FR2999575A1 (fr) * 2012-12-18 2014-06-20 Centre Nat Rech Scient 3,5-diaryl-azaindoles comme inhibiteurs de la proteine dyrk1a pour le traitement des deficiences cognitives liees au syndrome de down et a la maladie d'alzheimer
JP6487921B2 (ja) * 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
WO2017094026A1 (en) 2015-11-30 2017-06-08 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as new anticancer agents and the process for the preparation thereof
WO2018136202A2 (en) * 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018174650A1 (ko) * 2017-03-23 2018-09-27 재단법인 대구경북첨단의료산업진흥재단 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
US11447505B1 (en) 2017-08-18 2022-09-20 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
CN110759892B (zh) * 2018-07-26 2022-09-13 南开大学 Meridianin类衍生物及其制备和在防治植物病毒病菌病中的应用
CN109096257B (zh) * 2018-08-09 2020-02-21 山东博苑医药化学有限公司 Meridianin类生物碱及其衍生物在防治植物病毒病菌病中的应用
KR20200090637A (ko) 2019-01-18 2020-07-29 보로노이바이오 주식회사 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도
CN109879874A (zh) * 2019-03-05 2019-06-14 常州大学 一种Meriolin的合成方法
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
US20240261297A1 (en) * 2021-05-20 2024-08-08 St. John's Cancer Institute Anti-cdk inhibitors for cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
ES2345629T3 (es) * 2005-05-16 2010-09-28 Irm Llc Derivados de pirrolopiridina como inhibidores de proteina quinasas.
WO2007062998A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 3-amino-2-arylpropyl azaindoles and uses thereof

Also Published As

Publication number Publication date
US20100184790A1 (en) 2010-07-22
WO2008129152A1 (fr) 2008-10-30
FR2912744A1 (fr) 2008-08-22
EP2125803A1 (fr) 2009-12-02
JP2010518153A (ja) 2010-05-27
EP2125803B1 (fr) 2013-04-10
FR2912744B1 (fr) 2012-09-07

Similar Documents

Publication Publication Date Title
CA2678007A1 (fr) Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations
DE69815317T2 (de) Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
JP5820921B2 (ja) 1,2−二置換複素環式化合物
EP3024833B1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP5943053B2 (ja) フェノキシメチル複素環化合物
EP4285996A2 (en) Inhibitors of activin receptor-like kinase
JP2021105002A (ja) イミダゾピリダジン化合物
TW200520758A (en) Novel pharmaceuticals
EP3697786B1 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
TW201213324A (en) Fused heterocyclic compounds
FR2906250A1 (fr) Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
CA2766909C (fr) Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one,leur preparation et leur utilisation pharmaceutique
WO2004043936A1 (ja) Plk阻害剤
CN103619841A (zh) 杂芳基化合物及其使用方法
JP2020524148A (ja) 置換5−シアノインドール化合物及びその使用
CN103974954A (zh) 调节激酶的化合物、含有它们的组合物及其用途
JP2021535154A (ja) バニン阻害剤としてのヘテロ芳香族化合物
JP2008533172A (ja) チロシン/スレオニンキナーゼ阻害剤、特にB−RAFキナーゼ阻害剤としての、N−[3−(1−アミノ−5,6,7,8−テトラヒドロ−2,4,4b−トリアザフルオレン−9−イル)−フェニル]ベンズアミド
US9994590B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
KR102171706B1 (ko) 포스포디에스테라아제 10 효소의 억제제
JP6837072B2 (ja) 6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド化合物
HK1200815A1 (en) [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors
TW202227447A (zh) 嘧啶酮類化合物及其用途
TW201211043A (en) Tetrahydro-imidazo[1,5-a]pyrazine derivatives salts, preparation process and pharmaceutical use thereof

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121220

FZDE Discontinued

Effective date: 20150216